Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
NCT06644443Phase 2Recruiting
- Sponsor
- Shenzhen University General Hospital
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BMS-986453 in multiple myeloma (MM), sponsored by Shenzhen University General Hospital. Started Jul 2023; status: recruiting.
02
Drugs
BMS-986453
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06644443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644443.